Cancer testing lab earns agreement with national health care provider

FORT MYERS — NeoGenomics Inc., a leading provider of cancer-focused genetic testing services, has been awarded a group purchasing agreement for clinical reference laboratory testing services with Premier. Effective, Oct. 1, the new agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for clinical reference laboratory services.

“The agreement underscores NeoGenomics’ unique position as a national, oncology-focused laboratory,” says NeoGenomics Chairman and CEO Douglas VanOort in a statement. “We look forward to providing a comprehensive suite of cancer tests to Premier members across the country.”

Based in Fort Myers, NeoGenomics provides expert bone marrow and surgical pathology consults, cancer cytogenetics with industry-leading turnaround times, hematologic and solid tumor FISH testing with the largest menu of technical-only services available, 10-color flow cytometry, histology supported by an extensive IHC antibody library, and >150 molecular oncology tests comprising the most comprehensive combination of multi-method tumor profiles and targeted biomarker tests in the industry.

Premier is a leading health care improvement company aligned with approximately 4,000 U.S. hospitals and 165,000 other providers.